The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells
- PMID: 26166259
- PMCID: PMC7110702
- DOI: 10.1016/j.pupt.2015.07.001
The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells
Abstract
Background: Serine proteases act through the proteolytic cleavage of the hemagglutinin (HA) of influenza viruses for the entry of influenza virus into cells, resulting in infection. However, the inhibitory effects of serine protease inhibitors on influenza virus infection of human airway epithelial cells, and on their production of inflammatory cytokines are unclear.
Methods: Primary cultures of human tracheal epithelial cells were treated with four types of serine protease inhibitors, including camostat, and infected with A/Sendai-H/108/2009/(H1N1) pdm09 or A/New York/55/2004(H3N2).
Results: Camostat reduced the amounts of influenza viruses in the supernatants and viral RNA in the cells. It reduced the cleavage of an influenza virus precursor protein, HA0, into the subunit HA1. Camostat also reduced the concentrations of the cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-α in the supernatants. Gabexate and aprotinin reduced the viral titers and RNA levels in the cells, and aprotinin reduced the concentrations of TNF-α in the supernatants. The proteases transmembrane protease serine S1 member (TMPRSS) 2 and HAT (human trypsin-like protease: TMPRSS11D), which are known to cleave HA0 and to activate the virus, were detected at the cell membrane and in the cytoplasm. mRNA encoding TMPRSS2, TMPRSS4 and TMPRSS11D was detectable in the cells, and the expression levels were not affected by camostat.
Conclusions: These findings suggest that human airway epithelial cells express these serine proteases and that serine protease inhibitors, especially camostat, may reduce influenza viral replication and the resultant production of inflammatory cytokines possibly through inhibition of activities of these proteases.
Keywords: Airway epithelial cell; Camostat; Cell culture; Influenza; Interleukin; Serine protease.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Figures



Similar articles
-
The clinically used serine protease inhibitor nafamostat reduces influenza virus replication and cytokine production in human airway epithelial cells and viral replication in mice.J Med Virol. 2021 Jun;93(6):3484-3495. doi: 10.1002/jmv.26700. Epub 2020 Dec 17. J Med Virol. 2021. PMID: 33247612 Free PMC article.
-
Transcriptome profiling and protease inhibition experiments identify proteases that activate H3N2 influenza A and influenza B viruses in murine airways.J Biol Chem. 2020 Aug 14;295(33):11388-11407. doi: 10.1074/jbc.RA120.012635. Epub 2020 Apr 17. J Biol Chem. 2020. PMID: 32303635 Free PMC article.
-
The Proteolytic Activation of (H3N2) Influenza A Virus Hemagglutinin Is Facilitated by Different Type II Transmembrane Serine Proteases.J Virol. 2016 Apr 14;90(9):4298-4307. doi: 10.1128/JVI.02693-15. Print 2016 May. J Virol. 2016. PMID: 26889029 Free PMC article.
-
Aprotinin and similar protease inhibitors as drugs against influenza.Antiviral Res. 2011 Oct;92(1):27-36. doi: 10.1016/j.antiviral.2011.07.014. Epub 2011 Jul 23. Antiviral Res. 2011. PMID: 21802447 Review.
-
Airway proteases: an emerging drug target for influenza and other respiratory virus infections.Curr Opin Virol. 2017 Jun;24:16-24. doi: 10.1016/j.coviro.2017.03.018. Epub 2017 Apr 14. Curr Opin Virol. 2017. PMID: 28414992 Free PMC article. Review.
Cited by
-
Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery.Front Pharmacol. 2021 May 4;12:660710. doi: 10.3389/fphar.2021.660710. eCollection 2021. Front Pharmacol. 2021. PMID: 34017257 Free PMC article. Review.
-
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.mBio. 2021 Aug 31;12(4):e0097021. doi: 10.1128/mBio.00970-21. Epub 2021 Aug 3. mBio. 2021. PMID: 34340553 Free PMC article.
-
Immune Dysfunction and Multiple Treatment Modalities for the SARS-CoV-2 Pandemic: Races of Uncontrolled Running Sweat?Biology (Basel). 2020 Aug 24;9(9):243. doi: 10.3390/biology9090243. Biology (Basel). 2020. PMID: 32846906 Free PMC article. Review.
-
Advancements in Host-Based Interventions for Influenza Treatment.Front Immunol. 2018 Jul 10;9:1547. doi: 10.3389/fimmu.2018.01547. eCollection 2018. Front Immunol. 2018. PMID: 30042762 Free PMC article. Review.
-
Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.Signal Transduct Target Ther. 2020 May 29;5(1):84. doi: 10.1038/s41392-020-0191-1. Signal Transduct Target Ther. 2020. PMID: 32467561 Free PMC article. Review.
References
-
- Hayden F.G., Gwaltney J.M., Jr. Viral infections. In: Murray J., Nadel J.A., editors. Textbook of Respiratory Medicine. Saunders Co; Philadelphia: 1988. pp. 748–802.
-
- Perez-Padilla R., de la Rosa-Zamboni D., Ponce de Leon S., Hernandez M., Quinones-Falconi F., Bautista E. INER Working Group on influenza, Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N. Engl. J. Med. 2009;361:680–689. - PubMed
-
- Minor T.E., Dick E.C., Baker J.W., Ouellette J.J., Cohen M., Reed C.E. Rhinovirus and influenza type A infections as precipitants of asthma. Am. Rev. Respir. Dis. 1976;113:149–153. - PubMed
-
- Nichol K.L., Margolis K.L., Wuorenma J., Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N. Engl. J. Med. 1994;331:778–784. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials